Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1991-01-03
1993-08-17
Schenkman, Leonard
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514 54, 514174, 514179, 514459, A61K 3156
Patent
active
052369064
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to a dermatological composition for external use and more particularly to a topical dermatological composition which insures therapeutic efficacy at a sub-usual concentration of adrenocortical hormone.
BACKGROUND OF THE INVENTION
Adrenocortical hormone exhibits excellent efficacy in many diseases of the skin such as eczema/dermatitis represented by acute or chronic eczema, contact dermatitis, atopic dermatitis, etc., prurigo, e.g. strophulus and urticaria, cutaneous pruritus, psoriasis, etc. and as such has been widely used in clinical practice.
While adrenocortical hormone has very useful pharmacologic efficacy as aforesaid, long-term use of this hormone causes systemic side effects such as suppression of pituitary adrenocortical function even if it is externally used, not to speak of local skin infections and skin symptoms such as acne characteristic of this hormone. Therefore, for securing safety, the hormone is preferably used at a concentration as low as possible. However, any therapy with a topical preparation containing this hormone at such a low concentration cannot insure a sufficient therapeutic effect in such refractory diseases. To enhance the percutaneous absorption of adrenocortical hormone, it has been proposed to use this hormone in a topical therapeutic system containing a percutaneous absorption promoting agent such as urea, propylene glycol, etc. Another approach to this goal is the use of a therapeutic tape which takes advantage of the so-called occlusive dressing technique (ODT), such as Drenison Tape (Dainippon Pharmaceutical Co., Ltd., Japan). However, many problems such as skin irritation, inconvenience in use and so on remain to be solved. Under the circumstances, the advent of a topical therapeutic preparation which would be safe and easy to use has been keenly awaited. The inventor of the present invention explored the possibility of insuring a sufficient therapeutic effect with a topical preparation containing a reduced concentration of adrenocortical hormone and found that when hyaluronic acid is incorporated in a topical therapeutic composition containing adrenocortical hormone in such a reduced concentration, a therapeutic effect comparable to or even surpassing the effect obtainable with the conventional topical preparation containing the usual clinical dose of this hormone can be obtained. The present invention is predicated on the above finding.
SUMMARY OF THE INVENTION
This invention provides a topical therapeutic composition containing adrenocortical hormone and hyaluronic acid, the amount of said adrenocortical hormone being lower than the usual clinical dose of adrenocortical hormone.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a topical therapeutic composition containing adrenocortical hormone and hyaluronic acid, the amount of said adrenocortical hormone being lower than the usual clinical dose of adrenocortical hormone. The term `adrenocortical` hormone, as used in this specification means any and all of, inter alia, prednisolone, methylprednisolone, methylprednisolone acetate, prednisolone valerate acetate, cortisone, cortisone acetate, cortisone butyrate, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone butyrate propionate, flumethasone pivalate, triamcinolone, triamcinolone acetonide, dexamethasone, dexamethasone acetate, dexamethasone valerate, dexamethasone propionate, fluocinolone, fluocinolone acetonide, betamethasone, betamethasone valerate, betamethasone dipropionate, becromethasone propionate, clobetasone butyrate, fludroxycortide, fluocinonide, flunisolide, amcinonide, difluprednate, diflucortolone valerate, diflorasone acetate, clobetasol propionate and so on. Preferred are prednisolone, methylprednisolone, hydrocortisone acetate, hydrocortisone butyrate, flumethasone pivalate, dexamethasone acetate, fluocinolone, betamethasone valerate, betamethasone dipropionate, clobetasone butyrate, difluprednate, diflorasone acetate and clobetasol p
REFERENCES:
patent: 4736024 (1988-04-01), Della Valle et al.
Schenkman Leonard
Takeda Chemical Industries Ltd.
LandOfFree
Topical therapeutic preparation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical therapeutic preparation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical therapeutic preparation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2243796